Previous 10 | Next 10 |
After management reported that its oral selective complement 5a receptor inhibitor, avacopan, successfully treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis) in phase 3 studies, ChemoCentryx (NASDAQ: CCXI) shares...
Major benchmarks rose modestly on Tuesday, with market participants remaining optimistic as the Thanksgiving-shortened week continued. Despite a drop in consumer confidence and declining new home sales in the U.S., enthusiasm about a possible trade deal with China took center stage once again. S...
Gainers: ChemoCentryx (NASDAQ: CCXI ) +261% . More news on: ChemoCentryx, Inc., Akerna Corp., Proteostasis Therapeutics, Inc., Stocks on the move, Read more ...
ChemoCentryx ( CCXI +245.9% ) shares nearly quadruple in value after reporting positive results from its Phase 3 ADVOCATE study evaluating safety and efficacy of avacopan, an oral C5a receptor inhibitor. More news on: ChemoCentryx, Inc., Healthcare stocks news, Stocks on the move, ...
The biotech sector continues to grow as valuations are sky high, based on recent M&A’s within the industry. 2019 started off with a boom with the announcement of two multi-billion-dollar deals valued at a total $82 billion, one of them being among the top 10 highest valuations of a...
ChemoCentryx (NASDAQ: CCXI ) +323% on positive test results . More news on: ChemoCentryx, Inc., Nutanix, Inc., InflaRx N.V., Stocks on the move, Read more ...
MOUNTAIN VIEW, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 2:30 p.m. E...
Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care at 52 weeks Significantly reduced glucocorticoid toxicity Improved health-related quality of life measures compared to standard of care ...
Gainers: CCXI +305.7% . IFRX +24.1% . NTNX +19.2% . AMBA +6.6% . ETRN +3.8% . More news on: ChemoCentryx, Inc., InflaRx N.V., Nutanix, Inc., Stocks on the move, Read more ...
The company announces positive topline data from its pivotal phase III ADVOCATE trial for avacopan. More news on: ChemoCentryx, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...